Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.

摘要: We explored plasma and urinary concentrations of two members the vascular endothelial growth factor (VEGF) family their receptors as potential response toxicity biomarkers bevacizumab with neoadjuvant chemoradiation in patients localized rectal cancer. The VEGF, placental (PlGF), soluble VEGF receptor 1 (sVEGFR-1), sVEGFR-2 were measured urine at baseline during treatment. Pretreatment values changes over time analyzed pathological to treatment well for acute locally advanced cancer treated prospectively 2002-2008 bevacizumab, 5-fluorouracil, radiation therapy, surgery a phase I/II trial. Of all biomarkers, pretreatment sVEGFR-1-an endogenous blocker PlGF, linked "vascular normalization"-was associated both primary tumor regression development adverse events after chemoradiation. Based on findings this exploratory study, we propose that sVEGFR-1 should be further studied biomarker stratify future studies and/or cytotoxics setting.